MS Pharma and Bioeq Sign Deal for Ranibizumab in MENA.
Synopsis- MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland to commercialize the biosimilar candidate FYB201 (Ranibizumab)…
Synopsis- MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland to commercialize the biosimilar candidate FYB201 (Ranibizumab)…
FDA approved Genentech’s Susvimo, a port delivery system with a customized formulation of Ranibizumab, the active ingredient in Lucentis. Now, the trick for…